Teduglutide for treating short bowel syndrome

Graham Scotland; Daniel Kopasker; Neil Scott; Moira Cruickshank; Rodolfo Andrés Hernández; Cynthia Mary Fraser; Mairi McLean; Alistair McKinlay; Miriam Brazzelli

Teduglutide for treating short bowel syndrome

Graham Scotland, Daniel Kopasker, Neil Scott, Moira Cruickshank, Rodolfo Andrés Hernández, Cynthia Mary Fraser, Mairi McLean, Alistair McKinlay, Miriam Brazzelli

NHS Grampian

Research output: Book/Report › Commissioned Report

Abstract

Short bowel syndrome (SBS) is a rare and potentially life-threatening malabsorptive condition resulting from loss of significant mass of functional bowel or physical bowel. There are many reasons for loss of bowel mass, including congenital defects, disease (e.g. Crohn’s disease) and intestinal resection. Short bowel syndrome can affect both adults and children. People with SBS may also develop chronic Type III intestinal failure (SBS-IF), and require long-term parenteral support (PS), consisting of parenteral nutrition and/or intravenous fluids. Issues related to PS include catheter-related bloodstream infections, venous thrombosis, metabolic bone disease, liver damage and psychosocial and financial problems. Treatments for SBS-IF have
generally focused on optimising dietary interventions, and antisecretory and
antidiarrhoea medication, with surgery an option for a small number of patients. More recently, emphasis has been on promotion of intestinal rehabilitation and
improvement of absorption, including the use of the recombinant analogue of
glucagon-like peptide 2 (GLP-2).

Original language	English
Publisher	Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence
Number of pages	142
Publication status	Published - 20 Sept 2017

Bibliographical note

Scotland G, Kopasker D, Scott N, Cruickshank M, Hernández R, Fraser C, McLean M, McKinlay A, Brazzelli M. Teduglutide for treating short bowel syndrome. Aberdeen HTA Group, 2017

This report was commissioned by the NIHR HTA Programme as project number 15/07/04

Acknowledgements
The authors are grateful to Lara Kemp for her administrative support.
Copyright is retained by Shire for Tables 1, 3, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28 , 29, 39, 31, 32, and 33, and for Figures 1, 2, 5, 6 , 7, 9, 10, 11, and 12

Cite this

@book{df6e4dbfe6c44371b0f0bd4044dc214e,

title = "Teduglutide for treating short bowel syndrome",

abstract = "Short bowel syndrome (SBS) is a rare and potentially life-threatening malabsorptive condition resulting from loss of significant mass of functional bowel or physical bowel. There are many reasons for loss of bowel mass, including congenital defects, disease (e.g. Crohn{\textquoteright}s disease) and intestinal resection. Short bowel syndrome can affect both adults and children. People with SBS may also develop chronic Type III intestinal failure (SBS-IF), and require long-term parenteral support (PS), consisting of parenteral nutrition and/or intravenous fluids. Issues related to PS include catheter-related bloodstream infections, venous thrombosis, metabolic bone disease, liver damage and psychosocial and financial problems. Treatments for SBS-IF have generally focused on optimising dietary interventions, and antisecretory and antidiarrhoea medication, with surgery an option for a small number of patients. More recently, emphasis has been on promotion of intestinal rehabilitation and improvement of absorption, including the use of the recombinant analogue of glucagon-like peptide 2 (GLP-2).",

author = "Graham Scotland and Daniel Kopasker and Neil Scott and Moira Cruickshank and Hern{\'a}ndez, {Rodolfo Andr{\'e}s} and Fraser, {Cynthia Mary} and Mairi McLean and Alistair McKinlay and Miriam Brazzelli",

note = " Scotland G, Kopasker D, Scott N, Cruickshank M, Hern{\'a}ndez R, Fraser C, McLean M, McKinlay A, Brazzelli M. Teduglutide for treating short bowel syndrome. Aberdeen HTA Group, 2017 This report was commissioned by the NIHR HTA Programme as project number 15/07/04 Acknowledgements The authors are grateful to Lara Kemp for her administrative support. Copyright is retained by Shire for Tables 1, 3, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28 , 29, 39, 31, 32, and 33, and for Figures 1, 2, 5, 6 , 7, 9, 10, 11, and 12",

year = "2017",

month = sep,

day = "20",

language = "English",

publisher = "Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence",

}

TY - BOOK

T1 - Teduglutide for treating short bowel syndrome

AU - Scotland, Graham

AU - Kopasker, Daniel

AU - Scott, Neil

AU - Cruickshank, Moira

AU - Hernández, Rodolfo Andrés

AU - Fraser, Cynthia Mary

AU - McLean, Mairi

AU - McKinlay, Alistair

AU - Brazzelli, Miriam

N1 - Scotland G, Kopasker D, Scott N, Cruickshank M, Hernández R, Fraser C, McLean M, McKinlay A, Brazzelli M. Teduglutide for treating short bowel syndrome. Aberdeen HTA Group, 2017 This report was commissioned by the NIHR HTA Programme as project number 15/07/04 Acknowledgements The authors are grateful to Lara Kemp for her administrative support. Copyright is retained by Shire for Tables 1, 3, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28 , 29, 39, 31, 32, and 33, and for Figures 1, 2, 5, 6 , 7, 9, 10, 11, and 12

PY - 2017/9/20

Y1 - 2017/9/20

N2 - Short bowel syndrome (SBS) is a rare and potentially life-threatening malabsorptive condition resulting from loss of significant mass of functional bowel or physical bowel. There are many reasons for loss of bowel mass, including congenital defects, disease (e.g. Crohn’s disease) and intestinal resection. Short bowel syndrome can affect both adults and children. People with SBS may also develop chronic Type III intestinal failure (SBS-IF), and require long-term parenteral support (PS), consisting of parenteral nutrition and/or intravenous fluids. Issues related to PS include catheter-related bloodstream infections, venous thrombosis, metabolic bone disease, liver damage and psychosocial and financial problems. Treatments for SBS-IF have generally focused on optimising dietary interventions, and antisecretory and antidiarrhoea medication, with surgery an option for a small number of patients. More recently, emphasis has been on promotion of intestinal rehabilitation and improvement of absorption, including the use of the recombinant analogue of glucagon-like peptide 2 (GLP-2).

AB - Short bowel syndrome (SBS) is a rare and potentially life-threatening malabsorptive condition resulting from loss of significant mass of functional bowel or physical bowel. There are many reasons for loss of bowel mass, including congenital defects, disease (e.g. Crohn’s disease) and intestinal resection. Short bowel syndrome can affect both adults and children. People with SBS may also develop chronic Type III intestinal failure (SBS-IF), and require long-term parenteral support (PS), consisting of parenteral nutrition and/or intravenous fluids. Issues related to PS include catheter-related bloodstream infections, venous thrombosis, metabolic bone disease, liver damage and psychosocial and financial problems. Treatments for SBS-IF have generally focused on optimising dietary interventions, and antisecretory and antidiarrhoea medication, with surgery an option for a small number of patients. More recently, emphasis has been on promotion of intestinal rehabilitation and improvement of absorption, including the use of the recombinant analogue of glucagon-like peptide 2 (GLP-2).

UR - https://docslib.org/doc/786330/teduglutide-for-treating-short-bowel-syndrome

M3 - Commissioned Report

BT - Teduglutide for treating short bowel syndrome

PB - Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence

ER -

Teduglutide for treating short bowel syndrome

Abstract

Bibliographical note

Other files and links

Fingerprint

Cite this